BioXcel Therapeutics (BTAI) Short Interest Ratio & Short Volume $1.44 +0.02 (+1.48%) As of 12:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BioXcel Therapeutics Short Interest DataBioXcel Therapeutics (BTAI) has a short interest of 88,000 shares, representing 1.93% of the float (the number of shares available for trading by the public). This marks a 18.44% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 2.99 million shares to cover all short positions.Current Short Interest88,000 sharesPrevious Short Interest74,300 sharesChange Vs. Previous Month+18.44%Dollar Volume Sold Short$162,800.00Short Interest Ratio0.0 Days to CoverLast Record DateApril 30, 2025Outstanding Shares6,056,000 sharesFloat Size4,550,000 sharesShort Percent of Float1.93%Today's Trading Volume30,869 sharesAverage Trading Volume2,990,712 sharesToday's Volume Vs. Average1% Short Selling BioXcel Therapeutics? Sign up to receive the latest short interest report for BioXcel Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartBTAI Short Interest Over TimeBTAI Days to Cover Over TimeBTAI Percentage of Float Shorted Over Time BioXcel Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202588,000 shares $162,800.00 +18.4%1.9%0 $1.85 4/15/202574,300 shares $135,226.00 -66.6%1.6%0 $1.82 3/31/2025222,700 shares $452,081.00 +0.6%4.9%0.1 $2.03 3/15/2025221,300 shares $471,369.00 -33.0%8.1%0.1 $2.13 2/28/2025330,500 shares $713,880.00 +16.2%12.1%0.1 $2.16 2/15/2025284,500 shares $657,195.00 +13.5%11.0%2 $2.31 1/31/2025250,700 shares $1.31 million -84.3%9.7%2.1 $5.22 1/15/20251,600,000 shares $554,400.00 +98.1%N/A1.1 $0.35 12/31/2024807,700 shares $301,999.03 -23.1%N/A1 $0.37 12/15/20241,050,000 shares $432,705.00 +16.8%N/A1.7 $0.41 Get the Latest News and Ratings for BTAI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/30/2024898,700 shares $367,298.69 +44.0%N/A1.4 $0.41 11/15/2024624,100 shares $354,676.03 +79.8%N/A1.2 $0.57 10/31/2024347,100 shares $231,446.28 -39.8%N/A0.7 $0.67 10/15/2024576,400 shares $327,913.96 +11.6%N/A1.2 $0.57 9/30/2024516,400 shares $315,004.00 -26.0%N/A0.9 $0.61 9/15/2024697,600 shares $474,368.00 +2.5%N/A1.1 $0.68 8/31/2024680,500 shares $418,507.50 -6.9%N/A1.2 $0.62 8/15/2024731,200 shares $497,216.00 -9.4%N/A1.2 $0.68 7/31/2024807,300 shares $904,176.00 +28.9%N/A1.2 $1.12 7/15/2024626,100 shares $763,842.00 -61.4%N/A1 $1.22 6/30/20241,620,000 shares $2.07 million +8.7%N/A2.8 $1.28 6/15/20241,490,000 shares $2.04 million +0.7%N/A2.9 $1.37 5/31/20241,480,000 shares $2.68 million -9.2%N/A2.6 $1.81 5/15/20241,630,000 shares $3.36 million +8.7%N/A2.8 $2.06 4/30/20241,500,000 shares $3.78 million -28.2%N/A1 $2.52 4/15/20242,090,000 shares $5.75 million -16.1%N/A1.4 $2.75 3/31/20242,490,000 shares $7.02 million -20.7%10.5%1.7 $2.82 3/15/20243,140,000 shares $8.42 million -20.9%14.6%2.1 $2.68 2/29/20243,970,000 shares $12.62 million -46.8%18.7%2.6 $3.18 2/15/20247,460,000 shares $26.78 million +203.3%35.2%4.9 $3.59 1/31/20242,460,000 shares $7.92 million -17.5%11.9%2.1 $3.22 1/15/20242,980,000 shares $7.84 million +0.3%14.4%1.1 $2.63 12/31/20232,970,000 shares $8.76 million +3.5%14.7%1 $2.95 12/15/20232,870,000 shares $9.30 million -16.6%14.2%0.9 $3.24 11/30/20233,440,000 shares $13.07 million -32.3%17.0%1.1 $3.80 11/15/20235,080,000 shares $22.35 million -12.6%25.1%1.6 $4.40 10/31/20235,810,000 shares $23.33 million +16.9%28.8%1.9 $4.02 10/15/20234,970,000 shares $15.56 million +38.8%24.6%3.6 $3.13 9/30/20233,580,000 shares $9.06 million -24.6%17.7%2.4 $2.53 9/15/20234,750,000 shares $15.87 million +8.0%23.5%1.6 $3.34Musk’s Project Colossus could mint millionaires (Ad)I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.All the details are waiting for you now — but you need to act before the May 1st funding window clos 8/31/20234,400,000 shares $16.63 million -34.8%21.8%1.5 $3.78 8/15/20236,750,000 shares $27.95 million -4.1%33.5%2.3 $4.14 7/31/20237,040,000 shares $64.35 million -18.8%35.0%2.7 $9.14 7/15/20238,670,000 shares $89.30 million +69.0%43.1%3.5 $10.30 6/30/20235,130,000 shares $34.17 million +12.3%25.5%2.2 $6.66 6/15/20234,570,000 shares $98.26 million +22.9%22.7%8.3 $21.50 5/31/20233,720,000 shares $66.74 million +11.0%18.5%6.2 $17.94 5/15/20233,350,000 shares $91.22 million -5.4%16.7%6.5 $27.23 4/30/20233,540,000 shares $72.99 million -5.1%17.7%6.9 $20.62 4/15/20233,730,000 shares $69.90 million +3.6%18.6%7.4 $18.74 3/31/20233,600,000 shares $67.18 million +21.2%18.3%7.2 $18.66 3/15/20232,970,000 shares $58.21 million +5.7%15.1%6.3 $19.60 2/28/20232,810,000 shares $89.70 million +8.9%14.7%8 $31.92 2/15/20232,580,000 shares $84.29 million +5.3%13.5%7.6 $32.67 1/31/20232,450,000 shares $69.87 million +5.6%12.9%7.4 $28.52 1/15/20232,320,000 shares $67.14 million -3.3%12.2%8.1 $28.94 12/30/20222,400,000 shares $51.55 million +10.1%12.6%9.4 $21.48 12/15/20222,180,000 shares $44.04 million -4.4%11.5%9 $20.20 11/30/20222,280,000 shares $37.78 million -3.4%12.0%10.2 $16.57 11/15/20222,360,000 shares $38.00 million -6.7%12.4%10.9 $16.10 10/31/20222,530,000 shares $31.85 million -4.2%13.3%11.7 $12.59 10/15/20222,640,000 shares $27.06 million -5.7%13.9%11.1 $10.25 9/30/20222,800,000 shares $33.10 million -2.1%14.7%10.4 $11.82 9/15/20222,860,000 shares $37.95 million -2.4%15.0%8.5 $13.27 8/31/20222,930,000 shares $40.08 million -0.3%15.4%6.9 $13.68 8/15/20222,940,000 shares $44.86 million +7.7%15.5%6.1 $15.26 7/31/20222,730,000 shares $42.15 million -5.5%14.4%5 $15.44 7/15/20222,890,000 shares $48.70 million -19.7%15.2%5 $16.85 6/30/20223,600,000 shares $47.52 million -9.3%19.0%4 $13.20 6/15/20223,970,000 shares $39.14 million -1.2%20.9%4.4 $9.86 5/31/20224,020,000 shares $47.03 million -2.9%21.2%4.8 $11.70 5/15/20224,140,000 shares $48.60 million +5.3%21.8%5.2 $11.74 4/30/20223,930,000 shares $51.52 million -3.0%20.7%5.3 $13.11 4/15/20224,050,000 shares $63.10 million +97.6%21.4%5.7 $15.58 3/31/20222,050,000 shares $42.87 million +9.0%10.8%3.3 $20.91 3/15/20221,880,000 shares $28.31 million +0.5%9.9%6.1 $15.06 2/28/20221,870,000 shares $34.24 million +10.7%9.9%6.5 $18.31 2/15/20221,690,000 shares $31.38 million -5.1%8.9%5.4 $18.57 1/31/20221,780,000 shares $30.08 million -0.6%9.4%5.5 $16.90 1/15/20221,790,000 shares $34.91 million +3.5%9.4%5.9 $19.50 12/31/20211,730,000 shares $35.17 million -11.7%9.1%5.7 $20.33 12/15/20211,960,000 shares $42.59 million -1.0%10.3%6.7 $21.73 11/30/20211,980,000 shares $45.40 million +10.6%10.4%6.9 $22.93 11/15/20211,790,000 shares $48.71 million -4.3%9.4%6.6 $27.21 10/29/20211,870,000 shares $54.49 million +8.1%9.9%7.5 $29.14 10/15/20211,730,000 shares $46.87 million -6.0%9.1%6.7 $27.09 9/30/20211,840,000 shares $55.84 million -3.2%9.7%6.9 $30.35 9/15/20211,900,000 shares $56.51 million -6.9%10.0%5.4 $29.74 8/31/20212,040,000 shares $60.08 million -8.1%10.8%5.4 $29.45 8/13/20212,220,000 shares $54.59 million -5.9%11.8%5.9 $24.59Musk’s Project Colossus could mint millionaires (Ad)I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.All the details are waiting for you now — but you need to act before the May 1st funding window clos 7/30/20212,360,000 shares $60.39 million -9.9%12.6%6.1 $25.59 7/15/20212,620,000 shares $70.11 million -11.8%14.0%6.8 $26.76 6/30/20212,970,000 shares $86.31 million +2.1%16.9%7.7 $29.06 6/15/20212,910,000 shares $108.60 million -5.5%19.2%7.8 $37.32 5/28/20213,080,000 shares $101.73 million -3.1%20.3%7.8 $33.03 5/14/20213,180,000 shares $96.67 million -5.6%21.0%7.3 $30.40 4/30/20213,370,000 shares $116.27 million -7.7%22.3%7.1 $34.50 4/15/20213,650,000 shares $127.57 million +9.0%N/A7 $34.95 3/31/20213,350,000 shares $137.69 million -9.7%21.4%6.1 $41.10 3/15/20213,710,000 shares $174.33 million +2.8%23.8%6.5 $46.99 2/26/20213,610,000 shares $199.09 million +1.1%23.4%6.7 $55.15 2/12/20213,570,000 shares $230.62 million +5.6%23.1%6.8 $64.60 1/29/20213,380,000 shares $156.33 million -7.9%23.0%6.6 $46.25 1/15/20213,670,000 shares $198.55 million +10.2%25.0%7.7 $54.10 12/31/20203,330,000 shares $163.90 million +4.4%22.7%6.9 $49.22 12/15/20203,190,000 shares $147.89 million -2.5%21.8%7.2 $46.36 11/30/20203,270,000 shares $145.81 million +10.9%22.3%7.2 $44.59 11/15/20202,950,000 shares $160.13 million +4.2%20.1%6.2 $54.28 10/30/20202,830,000 shares $133.15 million +22.0%22.4%5.2 $47.05 10/15/20202,320,000 shares $120.41 million -13.8%18.3%3.5 $51.90 9/30/20202,690,000 shares $116.64 million +17.0%21.3%3.9 $43.36 9/15/20202,300,000 shares $111.09 million +6.5%18.2%3.3 $48.30 8/31/20202,160,000 shares $88.02 million -10.4%17.1%3.1 $40.75 8/14/20202,410,000 shares $90.42 million -14.2%20.7%3.5 $37.52 7/31/20202,810,000 shares $127.46 million +30.1%22.3%4.6 $45.36 7/15/20202,160,000 shares $109.08 million -3.6%20.6%4.3 $50.50 6/30/20202,240,000 shares $118.74 million +137.3%21.3%4.8 $53.01 6/15/2020944,000 shares $44.91 million +39.9%9.0%2.1 $47.57 5/29/2020674,800 shares $31.42 million -13.6%6.4%1.4 $46.56 BTAI Short Interest - Frequently Asked Questions What is BioXcel Therapeutics' current short interest? Short interest is the volume of BioXcel Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 88,000 shares of BTAI short. 1.93% of BioXcel Therapeutics' shares are currently sold short. Learn More on BioXcel Therapeutics' current short interest. What is a good short interest percentage for BioXcel Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.93% of BioXcel Therapeutics' floating shares are currently sold short. Is BioXcel Therapeutics' short interest increasing or decreasing? BioXcel Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 88,000 shares, an increase of 18.4% from the previous total of 74,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is BioXcel Therapeutics' float size? BioXcel Therapeutics currently has issued a total of 6,056,000 shares. Some of BioXcel Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. BioXcel Therapeutics currently has a public float of 4,550,000 shares. How does BioXcel Therapeutics' short interest compare to its competitors? 1.93% of BioXcel Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to BioXcel Therapeutics: bluebird bio, Inc. (4.42%), Kezar Life Sciences, Inc. (1.11%), FibroGen, Inc. (3.72%), Marinus Pharmaceuticals, Inc. (3.95%), MiNK Therapeutics, Inc. (2.29%), Allakos Inc. (0.37%), Scilex Holding (5.79%), CalciMedica, Inc. (1.09%), Surrozen, Inc. (0.90%), Generation Bio Co. (2.47%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short BioXcel Therapeutics stock? Short selling BTAI is an investing strategy that aims to generate trading profit from BioXcel Therapeutics as its price is falling. BTAI shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against BioXcel Therapeutics? A short squeeze for BioXcel Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BTAI, which in turn drives the price of the stock up even further. How often is BioXcel Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BTAI, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies BLUE Short Squeeze KZR Short Squeeze FGEN Short Squeeze MRNS Short Squeeze INKT Short Squeeze ALLK Short Squeeze SCLX Short Squeeze CALC Short Squeeze SRZN Short Squeeze GBIO Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BTAI) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
